<DOC>
	<DOCNO>NCT00411567</DOCNO>
	<brief_summary>The purpose study investigate/assess treatment moderate severe asthmatic inhaled corticosteroid .</brief_summary>
	<brief_title>A Study Assess Efficacy Inhaled Corticosteroid ( ICS ) Therapy Moderate-Severe Bronchial Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Male and/or female moderate severe asthmatic patient , 1875 year age . Moderate severe asthma , accord GINA guideline , least one year exacerbation require hospitalization and/or oral steroid within previous three month . No concomitant lung disease significant medical condition Fluticasone propionate 500mcg daily great , equivalent ( Mometsaone 800 mcg , triamcinolone 2000 mcg , Flunisolide 2000 mcg , Budesonide DPI 800 mcg , Beclomathasone HFA 500 mcg , Beclomethasone CFC 1000 mcg , Forced expiratory volume 1 second ( FEV1 ) screen ≥ 70 % normal predict . Evidence asthma , demonstrate one following : Historical evidence confirm treat physician Demonstration ≥ 12 % reversibility FEV1 use standard dose salbutamol ( 400 µg ) within 30 minute . Female subject child bear potential must use two form contraception postmenopausal woman must regular menstrual bleeding least 2 year prior inclusion . Body Mass Index 18 30 . Body weight less 100 kg . Smokers Concomitant medication : Except short longacting βagonists medication may require treat adverse event , medication , study drug avoid screening study completion evaluation conduct . Paracetamol acceptable . Medical condition : history clinically significant drug allergy ; significant medical condition . For example , history pulmonary disorder asthma . Any surgical medical condition might significantly alter distribution , metabolism excretion drug . Participation clinical investigation within 4 week prior dose longer required local regulation . Donation loss 400 mL blood within 8 week prior dose longer required local regulation . Significant illness within two week prior dose . A past personal close family medical history clinically significant cardiac abnormality History history fainting , orthostatic hypotension , sinus arrhythmia , etc . A known hypersensitivity Fluticasone propionate drug similar Fluticasone propionate . History immunocompromise , include positive HIV test result . A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . History drug alcohol abuse within 12 month prior dose Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>marker , inflammation , optimal , sub-optimal , corticosteroid , bronchial asthma</keyword>
</DOC>